Monoprost (Latanoprost)

Latanoprost binds to FP receptors in the eye, triggering biochemical changes that remodel the extracellular matrix of the ciliary body. This increases uveoscleral outflow of aqueous humor, thereby lowering intra‑ocular pressure and providing therapeutic benefit in glaucoma and ocular hypertension.

The dosing regimen for Monoprost is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the prescriber’s instructions.

Safety of latanoprost in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Monoprost, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monoprost (latanoprost) is a prostaglandin analog, a class known for once‑daily dosing and strong intra‑ocular pressure reduction. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, prostaglandin analogs often achieve greater pressure lowering with a favorable dosing schedule, though individual response varies.

Monoprost should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light and moisture, and discard any solution that appears discolored or contaminated.

Monoprost is administered as a sterile eye drop. The patient should wash their hands, tilt the head back, pull down the lower eyelid to create a pocket, and place one drop into the conjunctival sac of the prescribed eye(s). Avoid touching the tip of the bottle to any surface.

Serious risks, though rare, include severe ocular inflammation such as uveitis, macular edema that can affect vision, and paradoxical increases in intra‑ocular pressure. Patients should report any sudden vision changes, eye pain, or redness to their eye care professional promptly.

Monoprost is contraindicated in patients with known hypersensitivity to latanoprost or any component of the formulation. It should also be avoided in eyes with active intra‑ocular inflammation, infection, or in patients who have had recent ocular surgery unless specifically directed by a physician.